Only ~20% of patients with advanced non–small-cell lung cancer will benefit from immunotherapy; thus, biomarkers are needed. We performed a retrospective analysis of peripheral blood biomarker expression in 154 patients with advanced non–small-cell lung cancer receiving immunotherapy. Five variables at baseline (smoking, Eastern Cooperative Oncology Group performance status, liver metastases, lactate dehydrogenase, and neutrophil/lymphocyte ratio) were combined in a prognostic score (EpSILoN), which significantly identified 3 prognostic groups.
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy
Bilancia M.;
2020-01-01
Abstract
Only ~20% of patients with advanced non–small-cell lung cancer will benefit from immunotherapy; thus, biomarkers are needed. We performed a retrospective analysis of peripheral blood biomarker expression in 154 patients with advanced non–small-cell lung cancer receiving immunotherapy. Five variables at baseline (smoking, Eastern Cooperative Oncology Group performance status, liver metastases, lactate dehydrogenase, and neutrophil/lymphocyte ratio) were combined in a prognostic score (EpSILoN), which significantly identified 3 prognostic groups.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
